GSE210130
Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer
shRNAs targeting METTL3 used to deplete METTL3 in castrate-resistant LNCaP:C42 prostate cancer cells and the effect on gene expression and splicing determined. Overall design: shRNA targeting METTL3 was used to deplete METTL3 in castrate-resistant but enzalutamide-sensitive LNCaP:C42 and the effect on basal gene expression and alternative splicing determined using RNA sequencing.